Denali Therapeutics Inc (DNLI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Denali Therapeutics Inc (DNLI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8143
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Denali Therapeutics Inc (Denali Therapeutics) is a clinical-stage biopharmaceutical company that focuses on the development of therapeutics for the treatment of neurodegenerative diseases. The company’s proprietary drug delivery platform technologies include antibody transport vehicle and enzyme transport vehicle designed to deliver large molecules across the blood-brain barrier (BBB). Its pipeline products are intended for the treatment of Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, lysosomal storage disorder MPS II, neurodegeneration, amyotrophic lateral sclerosis and other indications. The company has development and commercialization rights to all of its programs, including the programs partnered with Takeda. Denali Therapeutics is headquartered in South San Francisco, California, the US.

Denali Therapeutics Inc (DNLI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Denali Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
Denali Therapeutics Raises USD130 Million in Series B Financing 12
Denali Therapeutics Raises USD217 Million in Venture Financing 13
Denali Therapeutics Raises USD217 Million in Venture Financing 15
Partnerships 16
Centogene and Denali Therapeutics Enter into Agreement 16
AbCellera Biologics Enters into Agreement with Denali Therapeutics 17
Parkinson’s Institute and Denali Therapeutics Enter into Agreement 18
Lonza Enters into Agreement with Denali Therapeutics 19
Takeda Pharma and Denali Therapeutics to Enter into Agreement 20
Denali Therapeutics Enters into Research Agreement with Blaze Bioscience 21
Denali Therapeutics Enters into Research Agreement with ALS Therapy Development Institute 22
Licensing Agreements 23
Denali Therapeutics Enters into Licensing Agreement with Washington University School of Medicine 23
Denali Therapeutics Expands Licensing And Collaboration Agreement with F-star 24
Denali Therapeutics Enters Into Licensing Agreement With Genentech 26
Equity Offering 27
Denali Therapeutics Raises USD287.5 Million in IPO 27
Denali Therapeutics Raises USD30 Million in Private Placement of Shares 29
Denali Therapeutics Raises USD7.6 Million in Private Placement of Shares 30
Denali Therapeutics Raises USD88.7 Million in Private Placement of Shares 31
Denali Therapeutics Raises USD122.3 Million in Private Placement of Shares 32
Denali Therapeutics Raises USD35 Million in Private Placement of Shares 33
Denali Therapeutics Raises USD47 Million in Private Placement of Shares 34
Denali Therapeutics Raises USD9.7 Million in Private Placement of Shares 35
Denali Therapeutics Raises USD0.1 Million in Private Placement of Shares 36
Denali Therapeutics Raises USD39.1 Million in Private Placement of Shares 37
Acquisition 38
Denali Therapeutics to Acquire F-star Gamma 38
Denali Therapeutics Acquires Incro Pharma 39
Denali Therapeutics Inc – Key Competitors 40
Denali Therapeutics Inc – Key Employees 41
Denali Therapeutics Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
Aug 09, 2018: Denali Therapeutics reports second quarter 2018 financial results 43
May 11, 2018: Denali Therapeutics Reports First Quarter 2018 Financial Results 44
Mar 19, 2018: Denali Therapeutics Announces Fourth Quarter And Full Year 2017 Financial Results 45
Corporate Communications 46
Aug 07, 2018: Denali Therapeutics Appoints Dana Andersen, Ph.D., as Chief Technical and Manufacturing Officer 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Denali Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Denali Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Denali Therapeutics Raises USD130 Million in Series B Financing 12
Denali Therapeutics Raises USD217 Million in Venture Financing 13
Denali Therapeutics Raises USD217 Million in Venture Financing 15
Centogene and Denali Therapeutics Enter into Agreement 16
AbCellera Biologics Enters into Agreement with Denali Therapeutics 17
Parkinson's Institute and Denali Therapeutics Enter into Agreement 18
Lonza Enters into Agreement with Denali Therapeutics 19
Takeda Pharma and Denali Therapeutics to Enter into Agreement 20
Denali Therapeutics Enters into Research Agreement with Blaze Bioscience 21
Denali Therapeutics Enters into Research Agreement with ALS Therapy Development Institute 22
Denali Therapeutics Enters into Licensing Agreement with Washington University School of Medicine 23
Denali Therapeutics Expands Licensing And Collaboration Agreement with F-star 24
Denali Therapeutics Enters Into Licensing Agreement With Genentech 26
Denali Therapeutics Raises USD287.5 Million in IPO 27
Denali Therapeutics Raises USD30 Million in Private Placement of Shares 29
Denali Therapeutics Raises USD7.6 Million in Private Placement of Shares 30
Denali Therapeutics Raises USD88.7 Million in Private Placement of Shares 31
Denali Therapeutics Raises USD122.3 Million in Private Placement of Shares 32
Denali Therapeutics Raises USD35 Million in Private Placement of Shares 33
Denali Therapeutics Raises USD47 Million in Private Placement of Shares 34
Denali Therapeutics Raises USD9.7 Million in Private Placement of Shares 35
Denali Therapeutics Raises USD0.1 Million in Private Placement of Shares 36
Denali Therapeutics Raises USD39.1 Million in Private Placement of Shares 37
Denali Therapeutics to Acquire F-star Gamma 38
Denali Therapeutics Acquires Incro Pharma 39
Denali Therapeutics Inc, Key Competitors 40
Denali Therapeutics Inc, Key Employees 41
Denali Therapeutics Inc, Subsidiaries 42

List of Figures
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Denali Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Denali Therapeutics Inc (DNLI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As
    Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As - Strategy, SWOT and Corporate Finance Report Summary Tek Art Insaat Ticaret Turizm Sanayi Ve Yatirimlar As - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's …
  • Southern Maryland Electric Cooperative Inc:企業の戦略的SWOT分析
    Southern Maryland Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors an …
  • Aurora Spine Corp (ASG):企業の製品パイプライン分析2018
    Summary Aurora Spine Corp (Aurora) is a medical equipment provider that offers surgical tools. The company offers novel solutions in the spinal implant market through a range of minimally invasive, and regenerative spinal implant technologies. It develops and distributes spinal implant products whic …
  • The Brookwood Partnership Ltd:企業の戦略・SWOT・財務情報
    The Brookwood Partnership Ltd - Strategy, SWOT and Corporate Finance Report Summary The Brookwood Partnership Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • BioFire Diagnostics LLC:医療機器:M&Aディール及び事業提携情報
    Summary BioFire Diagnostics LLC (BioFire Diagnostics), formerly Idaho Technology Inc, a subsidiary of bioMerieux SA, is a molecular diagnostics company that offers molecular biology products. The company offers solutions for healthcare providers, labs and customers. It provides respiratory, meningit …
  • Kirby Corporation:企業の戦略・SWOT・財務情報
    Kirby Corporation - Strategy, SWOT and Corporate Finance Report Summary Kirby Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Blackline Safety Corp. (BLN):企業の財務・戦略的SWOT分析
    Blackline Safety Corp. (BLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Premier Farnell Ltd:企業の戦略的SWOT分析
    Premier Farnell Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Hillenbrand, Inc.:企業の戦略・SWOT・財務情報
    Hillenbrand, Inc. - Strategy, SWOT and Corporate Finance Report Summary Hillenbrand, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Chronos Therapeutics Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Chronos Therapeutics Ltd (Chronos) is a research company that offers drug discovery and development services. The company offers research and development, drug discovery, lead optimization, preclinical efficacy, IND enabling, screening, pipeline development and clinical trial services. Its p …
  • Nuri Telecom Co., Ltd. (040160):企業の財務・戦略的SWOT分析
    Nuri Telecom Co., Ltd. (040160) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Omega Diagnostics Group Plc (ODX):企業の財務・戦略的SWOT分析
    Summary Omega Diagnostics Group Plc (Omega) is a biotechnology company that provides in-vitro diagnostic products. The company provides products in the areas of allergy, food intolerance, autoimmune disease and infectious disease, among others. It also provides food intolerance and autoimmune tests …
  • DaVita Inc (DVA)-医療機器分野:企業M&A・提携分析
    Summary DaVita Inc (DaVita), formerly DaVita HealthCare Partners Inc., is a provider of dialysis services and integrated health care delivery and management services. The company is a provider of dialysis services in the US for patients with chronic kidney failure and end-stage renal disease (ESRD). …
  • Polo Resources Ltd (POL):石油・ガス:M&Aディール及び事業提携情報
    Summary Polo Resources Ltd (Polo Resources) is a natural resource and mine development investment company that evaluates, acquires, and develops substantial investments in companies and projects. The company also invests in exploration companies. It invests in the gold, oil and gas, coal, phosphate, …
  • Karyopharm Therapeutics Inc (KPTI):企業の財務・戦略的SWOT分析
    Karyopharm Therapeutics Inc (KPTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Toyobo Co Ltd (3101):企業の財務・戦略的SWOT分析
    Toyobo Co Ltd (3101) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • SCHOTT AG:戦略・SWOT・企業財務分析
    SCHOTT AG - Strategy, SWOT and Corporate Finance Report Summary SCHOTT AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Olmsted Medical Center:製薬・医療:M&Aディール及び事業提携情報
    Summary Olmsted Medical Center (OMC) is a healthcare service provider that offers patient care services. The center offers services in the areas of general surgery, podiatry, pain management, dermatology, plastic surgery, inpatient dietary services, pediatrics, diabetes education, neurology, psychia …
  • Bluefish Pharmaceuticals AB-製薬・医療分野:企業M&A・提携分析
    Summary Bluefish Pharmaceuticals AB (Bluefish Pharmaceuticals) is a manufacturer and distributor of generic pharmaceutical products. The company provides products for various therapeutic areas including cardiovascular, the central nervous system, gastrointestinal, diabetes, oncology, dermatology, re …
  • Engie Energia Chile SA (ECL):企業の財務・戦略的SWOT分析
    Engie Energia Chile SA (ECL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆